These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression. Modesti N, Garcia J, Debouck C, Peterlin M, Gaynor R. New Biol; 1991 Aug; 3(8):759-68. PubMed ID: 1931822 [Abstract] [Full Text] [Related]
23. Effects of the tat and nef gene products of human immunodeficiency virus type 1 (HIV-1) on transcription controlled by the HIV-1 long terminal repeat and on cell growth in macrophages. Murphy KM, Sweet MJ, Ross IL, Hume DA. J Virol; 1993 Dec; 67(12):6956-64. PubMed ID: 8230418 [Abstract] [Full Text] [Related]
25. Lack of responsiveness of a nuclear factor-kappaB-regulated promoter to transactivation by human immunodeficiency virus 1 Tat in HeLa cells. Kelly GD, Morris CB, Offermann MK. Virology; 1999 Oct 10; 263(1):128-38. PubMed ID: 10544088 [Abstract] [Full Text] [Related]
28. Retroviral vector with a CMV-IE/HIV-TAR hybrid LTR gives high basal expression levels and is up-regulated by HIV-1 Tat. Robinson D, Elliott JF, Chang LJ. Gene Ther; 1995 Jun 10; 2(4):269-78. PubMed ID: 7552987 [Abstract] [Full Text] [Related]
29. A structure-activity study of the inhibition of HIV-1 Tat-dependent trans-activation by mixmer 2'-O-methyl oligoribonucleotides containing locked nucleic acid (LNA), alpha-L-LNA, or 2'-thio-LNA residues. Arzumanov A, Stetsenko DA, Malakhov AD, Reichelt S, Sørensen MD, Babu BR, Wengel J, Gait MJ. Oligonucleotides; 2003 Jun 10; 13(6):435-53. PubMed ID: 15025911 [Abstract] [Full Text] [Related]
33. TAR-independent activation of the HIV-1 LTR: evidence that tat requires specific regions of the promoter. Berkhout B, Gatignol A, Rabson AB, Jeang KT. Cell; 1990 Aug 24; 62(4):757-67. PubMed ID: 2201451 [Abstract] [Full Text] [Related]
36. HIV-1 regulatory protein tat induces RNA binding proteins in central nervous system cells that associate with the viral trans-acting-response regulatory motif. Kundu M, Ansari SA, Chepenik LG, Pomerantz RJ, Khalili K, Rappaport J, Amini S. J Hum Virol; 1999 Aug 24; 2(2):72-80. PubMed ID: 10225209 [Abstract] [Full Text] [Related]
37. Efficient trans-activation by the HIV-2 Tat protein requires a duplicated TAR RNA structure. Berkhout B, Gatignol A, Silver J, Jeang KT. Nucleic Acids Res; 1990 Apr 11; 18(7):1839-46. PubMed ID: 2186367 [Abstract] [Full Text] [Related]
38. A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency. Emiliani S, Van Lint C, Fischle W, Paras P, Ott M, Brady J, Verdin E. Proc Natl Acad Sci U S A; 1996 Jun 25; 93(13):6377-81. PubMed ID: 8692823 [Abstract] [Full Text] [Related]
39. Human immunodeficiency virus type 1 Tat does not transactivate mature trans-acting responsive region RNA species in the nucleus or cytoplasm of primate cells. Chin DJ, Selby MJ, Peterlin BM. J Virol; 1991 Apr 25; 65(4):1758-64. PubMed ID: 1900539 [Abstract] [Full Text] [Related]
40. Formation of a small ribonucleoprotein particle between Tat protein and trans-acting response element in human immunodeficiency virus-infected cells. Pfeifer K, Bachmann M, Schröder HC, Weiler BE, Ugarkovic D, Okamoto T, Müller WE. J Biol Chem; 1991 Aug 05; 266(22):14620-6. PubMed ID: 1830589 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]